These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7916094)

  • 21. [Peripheral neuropathy unmasked by therapy with adrenal cortex hormones during myalgia-eosinophilia syndrome related to L-tryptophan].
    Moreaud O; Mezin P; De Saint Victor JF; Noelle B; Berger F; Pellat J
    Presse Med; 1994 Jun; 23(24):1138. PubMed ID: 7971839
    [No Abstract]   [Full Text] [Related]  

  • 22. Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan.
    Greenberg AS; Takagi H; Hill RH; Hasan A; Murata H; Falanga V
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):264-6. PubMed ID: 8708033
    [No Abstract]   [Full Text] [Related]  

  • 23. [Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake].
    Grangeia Tde A; Schweller M; Paschoal IA; Zambon L; Pereira MC
    J Bras Pneumol; 2007; 33(6):747-51. PubMed ID: 18200378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The lessons of eosinophilia-myalgia syndrome.
    Duffy J
    Hosp Pract (Off Ed); 1992 Apr; 27(4A):65-9, 73-80, 83-90. PubMed ID: 1560091
    [No Abstract]   [Full Text] [Related]  

  • 26. Tryptophan induced eosinophilia-myalgia syndrome: clinical and microscopic findings.
    Groves RW; Simpson KJ; Koblar S; Pitzalis C; Hay RJ
    J R Soc Med; 1992 Feb; 85(2):111-2. PubMed ID: 1538375
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of patients with diffuse fasciitis and eosinophilia associated with L-tryptophan ingestion.
    Beko E; Pervaiz S; Nanda V; Dhawan S
    Cutis; 1993 Apr; 51(4):266-70. PubMed ID: 8477608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia?
    Hudson JI; Pope HG; Daniels SR; Horwitz RI
    JAMA; 1993 Jun 23-30; 269(24):3108-9. PubMed ID: 8505810
    [No Abstract]   [Full Text] [Related]  

  • 30. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale.
    Mayeno AN; Gleich GJ
    Trends Biotechnol; 1994 Sep; 12(9):346-52. PubMed ID: 7765187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acute pleuropericarditis with eosinophilia after ingestion of tryptophan].
    Dell'Isola B; Rezgui N; Thiollieres JM; Labrousse J; Lissac J; Valcke JC
    Rev Med Interne; 1993 May; 14(5):353-4. PubMed ID: 8235154
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study.
    McKeon P; Swanwick G; Manley P
    Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case from practice (233). Eosinophilic myalgia syndrome].
    Hefti U; Steiger U
    Schweiz Rundsch Med Prax; 1991 Dec; 80(50):1421-2. PubMed ID: 1749884
    [No Abstract]   [Full Text] [Related]  

  • 39. Tryptophan. Current status and future trends for oral administration.
    Kaufman LD; Philen RM
    Drug Saf; 1993 Feb; 8(2):89-98. PubMed ID: 8452659
    [No Abstract]   [Full Text] [Related]  

  • 40. The eosinophilia myalgia syndrome: to be or not to be.
    Espinoza LR
    Semin Arthritis Rheum; 1997 Jun; 26(6):781-4. PubMed ID: 9213375
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.